

## Special Issue

# Advances in Cyto-reductive Surgery and Intraperitoneal Chemotherapy

### Message from the Guest Editors

Peritoneal carcinomatosis used to be a lethal condition regardless of its origin (gastrointestinal cancer, gynaecologic cancer or peritoneal mesothelioma). This has changed radically in the last several years. Today we know that peritoneal metastases can be prevented and even treated with curative intention. Although there have been promising results, there is still a lack of standardization regarding the multiple different HIPEC regimens used and the different techniques to administrate this intraperitoneal chemotherapy, with new options such as PIPAC and different indications. There are some aspects which are unclear, such as how to better identify who benefits the most from this multimodal treatment of cytoreductive surgery, intraperitoneal chemotherapy and perioperative chemotherapy. We are in need of new evidence in order to improve our treatment protocols and the radiologic identification and categorization of disease and patients. We also know that there might be patients with high risk of developing peritoneal metastases. We need to identify these patients in order to select those who would benefit from a proactive oncoprophylactic treatment.

### Guest Editors

Dr. Juan Jose Segura-Sampedro

1. General & Digestive Surgery Department, Hospital Universitario Son Espases, 07120 Palma de Mallorca, Spain
2. School of Medicine, University of the Balearic Islands, 07120 Palma de Mallorca, Spain
3. Health Research Institute of the Balearic Islands (IdISBa), 07120 Palma de Mallorca, Spain

Dr. Pedro Antonio Cascales-Campos

1. Departament of Oncologic Surgery, Hospital Clínic Universitario Virgen de la Arrixaca, CP 30150 Murcia, Spain
2. Instituto Murciano de Investigación Biosanitaria (IMIB-Arrixaca), CP 30150 Murcia, Spain

### Deadline for manuscript submissions

closed (31 December 2023)



## Cancers

an Open Access Journal  
by MDPI

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/98346](https://mdpi.com/si/98346)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)